Synopsys has entered into a cooperation agreement with activist investor Elliott Investment Management. This agreement includes the appointment of Elliott's managing partner, Jesse Cohn, as an independent director to Synopsys's board, expanding it to 11 members. The deal also establishes ownership limits and standstill provisions, formalizing Elliott's involvement while aiming to support Synopsys's strategy in the AI-driven chip industry.

IBM has received a $46.24 million contract modification from the U.S. Air Force for ongoing advisory and assistance support related to resource allocation and Civil Engineering programs. This modification, issued by the Air Force District of Washington Contracting Directorate, increases the total contract value to over $155.5 million and extends the work until July 2, 2029. The contract aims to optimize resource allocation and Civil Engineering programs for the Air Force, with $37.3 million in fiscal 2026 operation and maintenance funds obligated at the time of award.

Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS), providing an opportunity for investors who suffered losses to lead the litigation. The lawsuit alleges that Gossamer Bio failed to disclose critical information about their Phase 3 PROSERA study, specifically that patients at Latin American sites performed unusually well on a placebo, leading the study to miss its primary endpoint. Investors are encouraged to participate before the June 1, 2026, lead plaintiff deadline.

Residents of Port Huron Township are demanding repairs to a crumbling railway overpass near 24th Street and Griswold Road, citing safety concerns due to deteriorating concrete and muddy conditions. The main overpass is owned by Canadian National Railway (CN), which claims the structure is sound but needs maintenance, while a smaller, inoperable overpass is owned by CSX Rail. Community advocate "Trash the Clown" and City Councilwoman Teri Lamb have highlighted the issue, pushing for action from the railway companies.

Veralto Corporation has priced an offering of $725 million in senior notes due 2032 with a 4.850% interest rate, expected to close around June 1, 2026. The company intends to use the estimated net proceeds of $720.6 million for general corporate purposes, including refinancing debt and working capital. This debt issuance follows strong Q1 2026 financial results and an increased full-year EPS guidance.

Morgan Stanley increased its price target for HSBC Holdings (HSBC) from 1,419 GBp to 1,463 GBp, while maintaining an Equal Weight rating. This adjustment comes despite HSBC's fiscal Q1 2026 pretax profit falling short of estimates and the bank raising its credit loss forecast. The article also notes HSBC's underperformance compared to European rivals and a significant loss related to the collapse of a British mortgage lender, which has amplified regulatory scrutiny on the private credit industry.

Thermo Fisher Scientific Inc. (TMO) hosted its annual Investor Day, targeting a bold 7% organic revenue CAGR over the long term, a significant increase from its recent 1% Q1 2026 organic growth. The company emphasized its dominant position in life sciences and declared a quarterly cash dividend of $0.47 per common share. While TMO is considered a strong investment, the article suggests other AI stocks might offer greater upside potential.

Taylor Greenwald, CFO of IBEX Ltd, sold 964 common shares worth $30,867 to cover tax obligations, while simultaneously acquiring 3,333 performance-based shares that converted from PSUs. Following these transactions, Greenwald holds 62,230 common shares. InvestingPro analysis suggests IBEX is undervalued, trading at a low earnings multiple relative to near-term growth, and the company recently reported strong Q3 fiscal 2026 results and authorized a $20 million share repurchase program.

IDEXX Laboratories (IDXX) has integrated its SDMA kidney biomarker, an early kidney disease detector, into its most popular point-of-care chemistry profiles, Catalyst CLIPs. This integration will be rolled out to customers in the US and Canada at no additional cost, providing veterinarians with earlier detection capabilities compared to traditional methods. The move aims to scale the impact of IDEXX's diagnostic innovations through platforms veterinarians already utilize daily.

Stifel analyst Jonathan Block reconfirmed a Buy rating and $210 price target for Align Technology (ALGN) after reviewing an updated financial model and the company's latest 10-Q filing. The updated model incorporated recent clear aligner volume data and Align's Q1 2026 earnings report, which showed revenue of $1.04 billion, a 6.2% year-over-year increase, attributed to record clear aligner shipments and higher selling prices. The company's GAAP EPS for Q1 2026 was $1.57 per diluted share, up from $1.26 in Q1 2025, driven by improved gross margins, a lower tax rate, and share buybacks.